Rep. David Taylor Sells Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Key Points

• Representative David Taylor sold shares of Medpace Holdings, Inc. worth between $1,001 and $15,000 on July 23rd, as disclosed in a filing.
• Medpace reported earnings of $3.10 per share for the last quarter, exceeding analyst expectations by $0.10, and forecasted FY 2025 EPS guidance between 13.760 and 14.53.
• Recent analyst ratings have been mixed, with some downgrading Medpace to a "sell" and others maintaining a "hold" rating, leading to a consensus target price of $412.73.

Representative David Taylor (R-Ohio) recently sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on September 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on July 23rd. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) - DAVE" account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Marathon Petroleum NYSE: MPC on 8/14/2025.
• Purchased $15,001 - $50,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Salesforce NYSE: CRM on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/7/2025.

Medpace Trading Down 0.1%

Shares of MEDP traded down $0.48 during trading hours on Monday, reaching $486.50. 29,270 shares of the stock traded hands, compared to its average volume of 442,492. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The company's 50-day moving average price is $412.68 and its two-hundred day moving average price is $344.18. The company has a market cap of $13.67 billion, a P/E ratio of 36.29, a price-to-earnings-growth ratio of 3.06 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MEDP. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group increased its stake in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. Whittier Trust Co. increased its stake in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares in the last quarter. Employees Retirement System of Texas acquired a new position in Medpace during the 2nd quarter valued at approximately $36,000. Finally, Colonial Trust Co SC increased its stake in Medpace by 150.0% during the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after purchasing an additional 105 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of research reports. William Blair restated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Rothschild & Co Redburn cut shares of Medpace from a "buy" rating to a "neutral" rating and boosted their price objective for the company from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and boosted their price objective for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Finally, Truist Financial boosted their price objective on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $412.73.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Jesse J. Geiger sold 41,801 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the sale, the president directly owned 36,503 shares in the company, valued at $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock worth $74,111,427 in the last three months. 20.30% of the stock is owned by company insiders.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.